Core Viewpoint - UTime Limited will implement a share consolidation, converting every five Class A ordinary shares into one share, effective February 17, 2026 [1][2]. Group 1: Share Consolidation Details - The share consolidation was approved by the board of directors on January 20, 2026, and subsequently by shareholders at an extraordinary general meeting on January 26, 2026 [2]. - The final consolidation ratio of 5:1 was established by the board on January 26, 2026 [2]. - Shareholders also approved resolutions to increase authorized share capital and amend the memorandum and articles of association during the extraordinary meeting [2]. Group 2: Impact on Shareholders - The share consolidation will not change any shareholder's percentage ownership interest in the company, aside from minor adjustments for fractional shares [3]. Group 3: Company Overview - UTime Limited, trading under the Nasdaq ticker WTO, is involved in the design, development, production, sales, and brand operation of mobile devices both in China and globally [4]. - The company aims to provide cost-effective products and serves a broad customer base [4].

中概股收盘跌幅居前的个股为：博美集团跌38.08%，联代科技跌33.65%，华谌科技跌21.29%，惠普森医药跌 19.99%，MKDWELL Tech跌17.93%。(格隆汇) | 代码 | 名称 | 最新价 | 涨跌幅 ^ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | BGM | 博美集团 | 1.480 | -38.08% | -0.910 | 66.15万 | | WTO | 联代科技 | 0.730 | -33.65% | -0.370 | 274.46万 | | HCAI | 华谌科技 | 0.2440 | -21.29% | -0.0660 | 75.63万 | | CPHI | 惠普森医药 | 0.7281 | -19.99% | -0.1819 | 6.86万 | | MKDW | MKDWELL Tech | 2.380 | -17.93% | -0.520 | 173.67万 | ...

SHENZHEN, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO), a global technology company engaged in the design, development, and manufacturing of mobile devices and smart hardware products, today announced that its Shenzhen-based subsidiary, Shenzhen Liandai Technology Co., Ltd. (“Shenzhen Liandai”), has entered into a strategic Intentional Order Cooperation Agreement (the “Cooperation Agreement”) with Shenzhen Yunwei Digital Technology Co., Ltd. (“Shenzhen Yunwei Digital”) for the potent ...

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced plans to raise $10 million through a private placement, leading to a significant drop in its share price [1] - Following the announcement, shares of Intelligent Bio fell 19.7% to $7.65 [1] Stock Movements - Lavoro Limited (NASDAQ:LVRO) saw a substantial increase of 181%, reaching $1.2900 [4] - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 57.7% to $5.32 after issuing FY26 guidance, expecting US net sales of Linzess to be between $1.125 billion and $1.175 billion [4] - Brand Engagement Network, Inc. (NASDAQ:BNAI) jumped 56% to $3.6290 after entering a Vendor Services Project Agreement with a global advertising agency [4] - ChowChow Cloud International Holdings Limited (NYSE:CHOW) increased by 39.7% to $0.8500 due to year-over-year revenue and net income growth in H1 2025 [4] - Sidus Space, Inc. (NASDAQ:SIDU) gained 29% to $4.0314, marking a 470% surge over the past month [4] - Baidu, Inc. (NASDAQ:BIDU) rose 12.1% to $146.57 after announcing a proposed spin-off and Hong Kong listing of its AI unit [4] Declines - Outlook Therapeutics, Inc. (NASDAQ:OTLK) experienced a significant decline of 58% to $0.6632 after receiving a complete response letter from the FDA regarding its biologics license application [4] - ESH Acquisition Corp. (NASDAQ:ESHA) fell 23.5% to $14.68 [4] - Nuvve Holding Corp. (NASDAQ:NVVE) declined 15.3% to $2.1500 after announcing the closing of a private placement [4]

Group 1 - UTime's Hong Kong subsidiary, UTime Technology, has signed a procurement agreement worth nearly $10 million with Tumu Vertex for smart health devices [1] - The agreement includes an initial purchase order for 50,000 smart health devices, consisting of 25,000 units each of the UT-168 BT Blood Pressure Watch, UR08 ECG Smart Ring, UT-368 4G Blood Pressure Watch, and UR01 Smart Ring [1] - The first batch of products is scheduled for delivery in the first quarter of 2026, with joint quality control procedures established by both parties [1] Group 2 - UTime's CEO highlighted that this cooperation marks a significant strategic breakthrough in the North American market [1] - The order from Tumu Vertex reflects market recognition of UTime's technological capabilities and opens opportunities in the North American medical-grade wearable market [1] - UTime aims to leverage this opportunity to accelerate the development and implementation of next-generation health monitoring technologies [1]

Core Insights - UTime Limited has achieved a significant commercial breakthrough by signing a nearly $10 million procurement agreement with Tumu Vertex LLC for smart health devices, marking a strategic entry into the North American medical-grade wearable market [1][2][3] Group 1: Agreement Details - The signed Sales Agreement includes an initial purchase order for 50,000 premium smart health devices, specifically 25,000 units of the UT-168 BT Blood Pressure Watch, 25,000 units of the UR08 ECG Smart Ring, 25,000 units of the UT-368 4G Blood Pressure Watch, and 25,000 units of the UR01 Smart Ring [2][7] - The agreement adheres to internationally recognized trade frameworks, including FOB Hong Kong delivery, phased payments, and standardized quality assurance systems [2] Group 2: Strategic Importance - This collaboration is viewed as a significant strategic breakthrough for UTime in the North American market, demonstrating market recognition of its technological capabilities [3] - The partnership is expected to accelerate the development and implementation of next-generation health monitoring technologies within UTime's product portfolio [3] Group 3: Market Outlook - UTime anticipates explosive growth in the smart health device market due to increasing global health awareness and longer life expectancies [4] - The major purchase order is expected to strengthen UTime's position in the consumer electronics sector while laying a foundation for strategic growth in the medical technology field [4] Group 4: Company Overview - UTime Limited, trading under the NASDAQ ticker WTO, is engaged in the design, development, production, sales, and brand operation of mobile devices and smart wearable technology globally [5]

Core Viewpoint - UTime Limited will implement a reverse stock split at a ratio of 1-for-100, effective November 21, 2025, to increase its share price and comply with Nasdaq's minimum bid price requirement [1]. Company Overview - UTime Limited, trading under the NASDAQ ticker WTO, is involved in the design, development, production, sales, and brand operation of mobile devices both in China and globally, aiming to provide cost-effective products to a broad customer base [3]. Reverse Stock Split Details - The reverse stock split will not result in fractional shares; any fractional shares will be rounded up to the nearest whole share, and positions held electronically will be automatically updated [2]. - The Class A ordinary shares will begin trading on a split-adjusted basis on Nasdaq under the ticker symbol "WTO" starting November 21, 2025 [1].

Core Insights - UTime Limited is actively promoting its smart wearable devices in international markets through existing global distribution channels and partnerships [1][3] - The company is leveraging its experience in supply chain management and product development from the mobile device sector to introduce health-focused smart wearables, including smartwatches and smart rings [3][5] - The CEO of UTime Limited highlighted the growing consumer focus on personal health management as a significant market opportunity, indicating plans to explore new partnerships and markets [5] Company Overview - UTime Limited trades under the NASDAQ ticker WTO and is involved in the design, development, production, sales, and brand operation of mobile devices both in China and globally [5] - The company aims to provide cost-effective products and serves a broad customer base, emphasizing a balance of functional design and cost-effectiveness to enhance competitiveness in the international market [3][5]

Core Insights - UTime Limited is focusing on the application of artificial intelligence (AI) in health data analysis, particularly through the development of AI-based algorithm models for analyzing physiological data from wearable devices [1][4][6] Group 1: AI Technology Development - The company is creating models for hypertension risk assessment by integrating various health parameters such as blood pressure, heart rate, activity, and sleep [4] - UTime is also analyzing pulse wave morphology to assess cardiovascular health trends, aiming to provide users with insights into their health status [4][6] Group 2: Company Vision and Strategy - The CEO of UTime Limited emphasized that the goal is to derive deeper insights from data to help users understand their health trends earlier, indicating a long-term investment in technology [6] - UTime Limited operates under the NASDAQ ticker WTO and is involved in the design, development, production, sales, and brand operation of mobile devices both in China and globally [7]

Core Insights - UTime Limited has launched a smart ring product aimed at providing continuous health data monitoring, particularly during nighttime [1][3] - The smart ring focuses on daily activity tracking and female health cycle management, offering users comprehensive health insights [5][6] Product Features - The smart ring is designed to monitor multiple physiological parameters, including skin temperature, blood oxygen saturation (SpO2), respiratory rate, and heart rate variability (HRV) [5] - Its primary application is in sleep quality assessment, generating detailed sleep analysis reports by collecting data unobtrusively during sleep [5] Market Position - The CEO of UTime Limited, Mr. Hengcong Qiu, emphasized that the smart ring is a significant addition to the health wearable device market, addressing user needs for continuous and unobtrusive monitoring [6] - UTime Limited operates under the NASDAQ ticker WTO and is involved in the design, development, production, sales, and brand operation of mobile devices both in China and globally [6]